Skip to content
10-Q

Quarterly Report

CRISPR Therapeutics AG CRSP

0001193125-25-273337

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 6, 2025 95.3M sh
Shares Diluted Q3 2025 · Sep 30, 2025 91.31M sh
Shares Diluted Q3 2025 · Sep 30, 2025 88.12M sh
Shares Diluted Q3 2025 · Sep 30, 2024 85.23M sh
Shares Diluted Q3 2025 · Sep 30, 2024 83.99M sh
Capex Q3 2025 · Sep 30, 2025 $397K
Capex Q3 2025 · Sep 30, 2024 $1.65M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$252.46M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$92.74M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $286.5M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $298.26M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $225.67M
Stockholders Equity Q3 2025 · Sep 30, 2025 $1.92B
Stockholders Equity Q3 2025 · Jun 30, 2025 $1.71B
Stockholders Equity Q3 2025 · Mar 31, 2025 $1.83B
Stockholders Equity Q3 2025 · Dec 31, 2024 $1.93B
Stockholders Equity Q3 2025 · Sep 30, 2024 $1.94B
Stockholders Equity Q3 2025 · Jun 30, 2024 $1.98B
Stockholders Equity Q3 2025 · Mar 31, 2024 $2.08B
Stockholders Equity Q3 2025 · Dec 31, 2023 $1.88B
Current Liabilities Q3 2025 · Sep 30, 2025 $118.96M
Current Liabilities Q3 2025 · Dec 31, 2024 $87.78M
Total Liabilities Q3 2025 · Sep 30, 2025 $329.33M
Total Liabilities Q3 2025 · Dec 31, 2024 $309.95M
Current Assets Q3 2025 · Sep 30, 2025 $1.93B
Current Assets Q3 2025 · Dec 31, 2024 $1.94B
Total Assets Q3 2025 · Sep 30, 2025 $2.25B
Total Assets Q3 2025 · Dec 31, 2024 $2.24B
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.17
Eps Diluted Q3 2025 · Sep 30, 2025 −$5.12
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.01
Eps Diluted Q3 2025 · Sep 30, 2024 −$3.92
Eps Basic Q3 2025 · Sep 30, 2025 −$1.17
Eps Basic Q3 2025 · Sep 30, 2025 −$5.12
Eps Basic Q3 2025 · Sep 30, 2024 −$1.01
Eps Basic Q3 2025 · Sep 30, 2024 −$3.92
Sga Expense Q3 2025 · Sep 30, 2025 $16.93M
Sga Expense Q3 2025 · Sep 30, 2025 $55.14M
Sga Expense Q3 2025 · Sep 30, 2024 $17.42M
Sga Expense Q3 2025 · Sep 30, 2024 $54.85M
Rd Expense Q3 2025 · Sep 30, 2025 $58.9M
Rd Expense Q3 2025 · Sep 30, 2025 $201.28M
Rd Expense Q3 2025 · Sep 30, 2024 $82.16M
Rd Expense Q3 2025 · Sep 30, 2024 $238.5M
Net Income Q3 2025 · Sep 30, 2025 −$106.44M
Net Income Q3 2025 · Sep 30, 2025 −$450.99M
Net Income Q3 2025 · Jun 30, 2025 −$208.55M
Net Income Q3 2025 · Mar 31, 2025 −$136M
Net Income Q3 2025 · Sep 30, 2024 −$85.94M
Net Income Q3 2025 · Sep 30, 2024 −$328.94M
Net Income Q3 2025 · Jun 30, 2024 −$126.41M
Net Income Q3 2025 · Mar 31, 2024 −$116.59M
Operating Income Q3 2025 · Sep 30, 2025 −$132.06M
Operating Income Q3 2025 · Sep 30, 2025 −$509.81M
Operating Income Q3 2025 · Sep 30, 2024 −$110.13M
Operating Income Q3 2025 · Sep 30, 2024 −$401.98M
Revenue Q3 2025 · Sep 30, 2025 $889K
Revenue Q3 2025 · Sep 30, 2025 $2.65M
Revenue Q3 2025 · Sep 30, 2024 $602K
Revenue Q3 2025 · Sep 30, 2024 $1.62M